Arch Therapeutics Stock Gross Profit
| ARTH Stock | USD 0.18 0.02 10.00% |
Arch Therapeutics fundamentals help investors to digest information that contributes to Arch Therapeutics' financial success or failures. It also enables traders to predict the movement of Arch OTC Stock. The fundamental analysis module provides a way to measure Arch Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arch Therapeutics otc stock.
Arch |
Arch Therapeutics OTC Stock Gross Profit Analysis
Arch Therapeutics' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Arch Therapeutics Gross Profit | (35.84 K) |
Most of Arch Therapeutics' fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arch Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, Arch Therapeutics reported (35,837) of gross profit. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
Arch Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arch Therapeutics' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Arch Therapeutics could also be used in its relative valuation, which is a method of valuing Arch Therapeutics by comparing valuation metrics of similar companies.Arch Therapeutics is currently under evaluation in gross profit category among its peers.
Arch Fundamentals
| Return On Equity | -40.15 | |||
| Return On Asset | -1.14 | |||
| Operating Margin | (364.73) % | |||
| Current Valuation | 12.54 M | |||
| Shares Outstanding | 249.94 M | |||
| Shares Owned By Insiders | 14.58 % | |||
| Price To Earning | (16.36) X | |||
| Price To Book | 34.61 X | |||
| Price To Sales | 638.65 X | |||
| Revenue | 15.65 K | |||
| Gross Profit | (35.84 K) | |||
| EBITDA | (4.71 M) | |||
| Net Income | (5.28 M) | |||
| Cash And Equivalents | 55 K | |||
| Total Debt | 2.81 M | |||
| Debt To Equity | 2.62 % | |||
| Current Ratio | 0.82 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (4.46 M) | |||
| Earnings Per Share | (0.02) X | |||
| Target Price | 3.0 | |||
| Beta | 0.72 | |||
| Market Capitalization | 1.44 B | |||
| Total Asset | 2.6 M | |||
| Retained Earnings | (35.9 M) | |||
| Working Capital | 14.96 K | |||
| Current Asset | 18.02 K | |||
| Current Liabilities | 3.06 K | |||
| Net Asset | 2.6 M |
About Arch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arch Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Arch OTC Stock
Arch Therapeutics financial ratios help investors to determine whether Arch OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arch with respect to the benefits of owning Arch Therapeutics security.